Skip to Main Content

WASHINGTON — It’s arguably the most cutting-edge and potentially lucrative area of biomedical science and now, to protect their investments, companies commercializing CRISPR genome editing technology are looking to shore up their Washington bonafides.

But unlike their comrades in the conventional drug world, CRISPR lobbyists aren’t blitzing every office on Capitol Hill with a slate of pro-industry proposals. The goal is more understated: to make sure the companies with experimental treatments just now entering the clinic are unimpeded by government bureaucracies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!